Androisoxazol is an oral anabolic steroid derived from dihydrotestosterone. It is similar in structure to stanozolol, which carries a 2,3-pyrazole group instead of the 2,3-isoxazole modification used here. Danazol is another commercial 2,3-isoxazole, although this particular agent has minimal anabolic activity. Similar to stanozolol, androisoxazol is non-estrogenic, and displays a highly favorable balance of anabolic to androgenic effect. Depending on the source, it is identified as having an-anabolic to androgenic ratio ranging from 7:1, all the way up to 40:1. Although no longer available, this agent possesses strong muscle building and performance enhancing properties, which are accompanied by a low inclination for androgenic side effects. Being a non-estrogenic agent, androisoxazol is well suited for lean mass gains, cutting purposes, and competitive athletics.
|Brand name||Neo-Ponden, Androisoxazol|
|Progestational Activity||no data available|
Androisoxazol was first described in 1961. The drug was developed into a medicine by Serono, an international pharmaceuticals giant that was originally founded in- Italy in 1906 as Ares-Serono. Serono would sell the agent on the Italian drug market under the Neo-Ponden brand name. Androisoxazol was developed subsequent to the successful synthesis of stanozolol a couple of years earlier, which is another heterocyclic steroid with a favorable anabolic/androgenic profile. Numerous other A-ring heterocyclic DHT derivatives were synthesized around the same time as well, including thiazoles, pyridines, oxadiazoles, indoles, and triazoles. The isoxazole androisoxazol was found to be the most potent of this group, and most closely resembled stanozolol in its pharmacological properties.
Given its favorably low androgenic profile, androisoxazol was used clinically in a number of androgen sensitive patient populations including women, children, and the elderly. Although human studies on the drug are not extensive, it appears to have been used with success and safety in these populations. In spite of this fact, however, it was ultimately short lived as a commercial product. Serono would discontinue sale of the agent less than a decade after introducing it in Italy, long before there was great controversy surrounding the use of anabolic steroids in sports. Androisoxazol was rarely studied outside of this region, although isolated other products containing the drug (such as the brand Androxan) did exist for a short time. Today, all forms of this agent have been out of commerce for so long that few people have any knowledge of it.
How is Neo-Ponden Supplied
Androisoxazol is no longer available as a prescription agent. When manufactured, it came in the form of an oral tablet.
Structural Characteristics of Neo-Ponden
Androisoxazol is a modified form ofdihydrotestosterone.lt differs by: 1) the addition of a methyl group at carbon 17-alpha to protect the hormone during oral administration and 2) the attachment of an isoxazole group to the A-ring, replacing the normal 3-keto group, which increases anabolic strength while reducing relative androgenicity.
Neo-Ponden Side Effects (Estrogenic)
Androisoxazol is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention.
Neo-Ponden Side Effects (Androgenic)
Although classified as an anabolic steroid, androgenic side effects are still possible with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth,and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize androisoxazol, so its relative androgenicity is not affected by finasteride or dutasteride. This is a steroid with relatively low androgenic activity in relation to its tissue-building actions, making the threshold for strong androgenic side effects comparably higher than more androgenic agents such as testosterone, methandrostenolone, or fluoxymesterone.
Neo-Ponden Side Effects (Hepatotoxicity)
Androisoxazol is a cl 7-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. Cl 7-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of cl 7-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain.
Neo-Ponden Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Androisoxazol has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown, non-aromatizable nature, and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Neo-Ponden Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
Neo-Ponden Administration (General)
Prescribing guidelines generally advise that oral steroids can be taken with or without meals. The difference in bioavailability is generally not regarded as substantial. However, a 2016 study on newborn infants did find the absorption of oxandrolone to be significantly improved when dissolved directly in fat (MCT oil). If the diet includes considerable fat content, taking this oral steroid with meals might be more advantageous.
Neo-Ponden Administration (Men)
Androisoxazol was used in a clinical dose of .2mg per kg of bodyweight per day (.2mg/kg/d). This would equate to a daily dose of approximately 15 mg for a 175-pound male. It was taken for a maximum period of 60 consecutive days. An effective dosage for physique- or performanceenhancing purposes falls between 15 mg and 40 mg per day. The drug would be taken for no longer than 6-8 weeks to minimize potential hepatic stress. This level is sufficient for solid gains in lean muscle tissue, which may be accompanied by increased hardness and definition.
Neo-Ponden Administration (Women)
Androisoxazol was used in a clinical dose of .2mg per kg of bodyweight per day (.2mg/kg/d). This would equate to a daily dose of approximately 10 mg for a 120-pound female. In an effort to reduce the chance for virilization, it was recommended to take the drug only for 20 consecutive days, followed by a break of 10 days before resuming drug therapy. A total of no more than three 20-day cycles were recommended. An effective daily dosage for physique- or performance-enhancing purposes falls between 5-10 mg per day.The drug would be taken for no longer than 6-8 weeks to minimize potential hepatic stress.This level is sufficient for solid gains in lean muscle tissue, which may be accompanied by increased hardness and definition. Although this compound is mildly androgenic, the risk of virilization symptoms cannot be excluded.
Androisoxazol is no longer produced as a prescription drug product, and is unavailable on the black market.
Wlliam Llewellyn (2017) - Anabolics